Media ReleasesImmutep

View All Immutep News

Immutep, CEO Presentation Annual General Meeting November 2018

The global leader in developing LAG-3 therapeutics

2018 Summary

• Strong operational and financial progress

• Continued focus on LAG-3 immunotherapy

• Progressed the development of four LAG-3 based product candidates for cancer and auto immune disease

• Reported encouraging interim data for lead product candidate, IMP321 (‘efti’) from TACTI-mel trial

• Committed partnerships with five of the world’s largest pharmaceutical companies - Merck (MSD), Novartis and GSK, plus Merck (Germany) and Pfizer, along with Eddingpharm (EOC) in China

To view Presentation please download PDF attached:
Download this document